Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Enovis CORP ENOV

Compare with peers Embed
SEC comment letters, last 20 years

6 reviews of ENOV's filings by SEC staff

UPLOAD and CORRESP
Reviews 6 latest letter Dec 22, 2025
Questions asked 17 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 8 UPLOAD
  2. 2. Questions in them 17 numbered comments
  3. 3. Company replies 8 CORRESP
  4. 4. Reviews closed 4 of 6 closing letter

Half the closed reviews took 30 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2024

2025-12-22 to 2026-04-23 · 7 questions · 2 letters from the SEC, 2 from the company
Review closed 2026-04-23
Non-GAAP measuresResults discussion (MD&A)InventoryRevenueSegments
Operations · Non-GAAP Measures, page 31
SEC asked (2)
We reference your response to prior comment 1. It appears that the non-GAAP adjustment for the purchase of royalty interest is related to a normal recurring operating expense for which a non-GAAP adjustment would be inconsistent with Question 100.01 of the Compliance & Disclosure Interpretations (C&DI) for Non- GAAP Financial Measures.
Rest of the question

In that regard, we note that the underlying intellectual property developed in connection with the related agreements continues to be incorporated into the company's products. Therefore, it appears that those costs relate to the generation of revenue and would be considered normal operating expenses. Please revise your presentation to remove the adjustment for purchase of royalty interest from your Adjusted EBITDA measures in future filings as well as the presentation of Adjusted Net Income included in the press release on Form 8- K. Alternatively, tell us why you continue to believe that the adjustment is consistent with the C&DI.

ENOV answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.

Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.

Reworded

Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

71 words cut, 21 added sec.gov
Reworded

Net loss and Net loss from continuing operations increased $15.6 million during 2023 2025 in comparison to 2022, 2024, primarily due to one-time income items the increase in Goodwill impairment charges of $404.8 million, a $45.8 million increase in charges for the prior year period, including the Unrealized gain on investment Purchase of royalty interest and an $8.1 million increase in ESAB Corporation, Gain on cost basis investment, Insurance settlement gain, amortization of acquired intangibles, partially offset by the reduction of debt extinguishment charges and the aforementioned net impact of the Gross profit and Selling, general, and administrative increases as well as the increase in gross profit, a $48.0 million decrease in Interest restructuring and strategic transactions costs from Lima and other integration activities, and a $22.3 million decrease in interest expense, net and the impact of unfavorable discrete tax items in 2022. net. Adjusted EBITDA increased due to organic growth. Adjusted the growth in Recon and improved operating leverage.

64 words cut, 67 added sec.gov
Reworded

Net sales increased in Recon by $379.3 million, or 60%, of which $338.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a $4.3 million decrease from the discontinuance of certain non-core product lines. Comparable Sales Growth for Recon was driven by approximately 8.2% increase in volume and market share gains and favorable currency translation of 0.3%. Gross profit increased $179.1 million in the year ended December 31, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, and improved operating leverage, offset by an increase of $51.6 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by $207.6 $8.3 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased an increase in commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, sales and increases in existing business investments to support growth. growth, nearly entirely offset by a decrease in Lima Acquisition integration costs. Research and development expense increased compared to the prior year period due to the Lima Acquisition an increase in new product development projects and increased activities and spending within other our recently acquired businesses in our Recon segment, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due Purchase of royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a Goodwill impairment fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and recognized a $45.8 million charge of $330.0 million, a $48.9 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization net present value of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage. purchases.

223 words cut, 87 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Operations · Non-GAAP Measures, page 31
SEC asked (3)
Reference the non-GAAP adjustment related to Inventory step-up. Please tell us why you believe an adjustment for inventory step-up charges in connection with acquired businesses does not change the recognition and measurement principles required to be applied in accordance with GAAP. Refer to Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures.
Rest of the question

Alternatively, please revise your presentation to remove this non-GAAP adjustment to Adjusted net income and Adjusted EBITDA measures in future filings, including the presentation in the press release on Form 8-K.

ENOV answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.

Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.

Reworded

Net sales increased in Recon by $379.3 million, or 60%, of which $338.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a $4.3 million decrease from the discontinuance of certain non-core product lines. Comparable Sales Growth for Recon was driven by approximately 8.2% increase in volume and market share gains and favorable currency translation of 0.3%. Gross profit increased $179.1 million in the year ended December 31, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, and improved operating leverage, offset by an increase of $51.6 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by $207.6 $8.3 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased an increase in commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, sales and increases in existing business investments to support growth. growth, nearly entirely offset by a decrease in Lima Acquisition integration costs. Research and development expense increased compared to the prior year period due to the Lima Acquisition an increase in new product development projects and increased activities and spending within other our recently acquired businesses in our Recon segment, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due Purchase of royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a Goodwill impairment fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and recognized a $45.8 million charge of $330.0 million, a $48.9 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization net present value of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage. purchases.

223 words cut, 87 added sec.gov
Gone

Net sales increased for Recon in the year ended December 31, 2023 compared with the prior year, by $94.9 million, or 17.7%, primarily due to higher sales volumes driven by broad market strength and market outperformance. Gross profit increased in the year ended December 31, 2023 compared to the prior year, by $82.1 million, primarily due to increased sales in our existing businesses, improved operating cost leverage, and the benefit of a decrease of $12.7 million in inventory fair value step-up amortization charges, which also led to an increase in Gross profit margin. Selling, general and administrative expense increased $53.6 million, including an increase of $43.1 million, or 15%, due to the growth in Recon from increased commissions driven by higher sales, investments to support growth, spending on MDR, and cost inflation, as well as a net increase in Strategic transactions costs of $3.9 million from an increase in deal and integration costs for the Lima and Novastep acquisitions offset by a decrease of Separation costs. Research and development expense increased compared to the prior year period, primarily due to increased spend within recently acquired businesses which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss decreased primarily due to the aforementioned factors driving organic growth, offset by an insurance settlement gain recorded in the second quarter of 2022 and an increase of $6.2 million in amortization of acquired intangibles. Adjusted EBITDA increased primarily due to growth in existing businesses and operating leverage, partially offset by inflation of supply chain, logistics, and other costs. Without the impact of recent acquisitions, Adjusted EBITDA increased 150 basis points compared to prior year. The recent acquisitions of Novastep and 360 Med Care were dilutive to the margin by approximately 70 basis points but are expected to be accretive to margins in future years.

303 words cut, 0 added sec.gov
Reworded

Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

71 words cut, 21 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Operations · Non-GAAP Measures, page 31
SEC asked (4)
We note that you continue to include material non-GAAP adjustments for strategic transaction costs. Please tell us why you continue to adjust your non-GAAP measures for these costs and explain why they are not normal, recurring cash operating costs. With your response, please include information abut the expenses/(benefits) incurred through September 30, 2025.
Rest of the question

In addition, describe in more detail the nature of the payroll costs and retention expenses for which non-GAAP adjustments were made in 2024 and 2025. Please reference Question 100.01 of the C&DI for Non-GAAP Financial Measures.

ENOV answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.

Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.

Reworded

Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

71 words cut, 21 added sec.gov
New paragraph

(5) Strategic transaction costs includes: (i) $39.4 million for the year ended December 31, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $19.5 million for the year ended December 31, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $1.5 million for the year ended December 31, 2025 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

0 words cut, 263 added sec.gov
New paragraph

(5) Strategic transaction costs includes: (i) $64.9 million for the year ended December 31, 2024 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $8.8 million for the year ended December 31, 2024 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $4.6 million for the year ended December 31, 2024 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

0 words cut, 263 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Measures, page 31
SEC asked (1)
We have reviewed your response to comment 2 and we believe that the non-GAAP adjustment for the purchase of royalty interest is inconsistent with Question 100.01 of the Compliance & Disclosure Interpretations on Non-GAAP Financial Measures.
Rest of the question

Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.

ENOV answered

No numbered answer found in the reply. Read the reply ↗

In its next report

First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.

Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.

Reworded

Adjusted EBITDA excludes from Net income (loss) the effect of Loss Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other (income) expense, net; non-operating (gain) loss on investments; debt extinguishment charges; Interest expense, net; Restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and goodwill impairment charges; and fair value charges on acquired inventory. charges. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted Adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

70 words cut, 8 added sec.gov
Reworded

Operating loss increased, income increased primarily due to the Goodwill impairment charge decrease in Purchase of $318.6 million, slightly offset by royalty interest and inventory fair value step-up amortization charges, the aforementioned gross profit increases and a $6.5 $2.6 million decrease in strategic transaction costs including the integration and transaction costs for the Lima Acquisition. Adjusted EBITDA increased primarily due to the aforementioned sales growth and gross profit increase. increase, driven by higher net sales and a decrease of $12.1 million in inventory fair value step-up amortization charges.

12 words cut, 34 added sec.gov
New paragraph

(7) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, the following non-GAAP measures for the three months ended April 4, 2025 as presented in our Form 10-Q for the period ended April 4, 2025 have been revised to reflect the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses: Adjusted EBITDA for our Recon segment has been revised from $68.3 million to $56.2 million, Total Adjusted EBITDA has been revised from $99.2 million to $87.1 million, Adjusted EBITDA margin for our Recon segment has been revised from 23.9% to 19.6%, and Total Adjusted EBITDA margin has been revised from 17.7% to 15.6%.

0 words cut, 139 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Measures, page 31
SEC asked (2)
We have reviewed your response to comment 3 and we believe that the non-GAAP adjustment for Inventory step-up in connection with acquired businesses is inconsistent with Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures.
Rest of the question

Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.

ENOV answered
We respectfully acknowledge the Staff’s comment and advise the Staff that the Company continues to believe that its non-GAAP adjustment for the purchase of royalty interest is appropriate for the reasons set forth below, as well as those set forth in our prior responses to the Staff.

April 8, 2026

The adjustment reflects the one-time, non-recurring, up-front expense recognized by the Company to acquire third-party royalty interests, which represents the purchase of a long-term economic right rather than a cost incurred in the ordinary course of producing or delivering the Company’s products
Rest of the answer

or services. As described in the Company’s prior responses, the expense was incurred as part of a one-time, strategic decision to terminate existing product development agreements and acquire the associated royalty interests in connection with the transformation of the Company’s product development model and is fundamentally different from operating expenses incurred to run the Company’s business on a recurring basis. The Company does not anticipate entering into similar transactions on a recurring basis in connection with any future changes or additions to its core product development teams.

royalty buyouts were a foundational element of the Company’s transition to the new model, as they facilitated a shift in the way design surgeons are compensated for their development of the Company’s global product portfolio. The Company believes that this new model, which primarily aligns compensation with growth in the Company’s overall Reconstructive portfolio rather than individual products, will accelerate its pace of innovation by, among other things (i) incorporating new and diverse viewpoints to ensure that global and regional differences and preferences are considered in the product development process (which is of critical importance to the Company, given its expanded global reach following its acquisitions of Mathys and Lima), (ii) ensuring that the Company receives candid and unbiased guidance in integrating and rationalizing acquired product portfolios, (iii) placing additional emphasis on rapidly developing and expanding enabling technologies, and (iv) fostering an environment that encourages product development partners to provide strategic advice on research and development activities that cut across individual projects and product lines.

As noted above, a key benefit of the new model is the emphasis it places on candid and unbiased advice in the product development process. Under the Company’s legacy project-focused approach to innovation, product development partners were incentivized to devote their time and attention to projects to which they are assigned and to products for which they receive royalties. Consequently, these prominent partners with considerable clinical and design expertise may not be fully incentivized to provide broader ideas or innovative insights beyond the scope of their discrete engagements and may be less likely to provide high value innovative ideas to the Company in a project-focused setting because there are no incentives to do so.

Specifically, under the legacy model, if an idea for a next generation product could disrupt the existing portfolio or sunset certain products for which a product development partner currently receives royalties, they may be disincentivized from pursuing such an idea.

By terminating and buying out the royalty interests under the legacy agreements with its leading product development partners, the Company was able to significantly accelerate the shift to the new model by eliminating these disincentives, while also ensuring that it fulfilled its pre-existing contractual obligations under the legacy agreements through the negotiated settlements. The amounts to be paid each year under the buyout agreements are fixed and are not dependent on future operational factors. The buyout amounts were determined on an individual basis as a result of arm’s-length negotiations with the counterparties.

Additionally, the Company respectfully submits that the purchase of the royalty interest is not the type of “normal, recurring, cash operating expense” contemplated by Question

100.01 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures (each question thereof, a “C&DI”) because it is not a period operating cost incurred to generate current-period revenues, but rather a discrete transaction that restructures the economics of a pre-existing royalty arrangement by converting a contingent, sales-based obligation into a fixed purchase price. Stated differently, while ongoing royalties (if payable) may be recurring operating costs, the buyout of the royalty interest is a one-time strategic transaction to eliminate future contingent royalties and replace them with a single negotiated consideration amount and therefore is not indicative of the Company’s normal operating cost structure.

Further, to the extent the Staff’s “recurrence” concern is based on the fact that the acquired or underlying intellectual property may continue to be incorporated into the

Company’s products or that the purchase consideration may be settled over multiple periods, the Company respectfully submits that neither point changes the nature of the item being adjusted. The relevant question under Question 100.01 of the C&DI is whether the adjustment removes a normal, recurring operating expense, and the Staff has emphasized that the analysis turns on the nature and effect of the adjustment in the context of the business—not the timing of cash settlement. Here, the purchase reflects a discrete, negotiated restructuring of an economic right; once executed, the Company’s future recurring royalty expense under the terminated agreements is eliminated, rather than being

“normalized” out of operating results.

adjustment isolates a transaction that is fundamentally different from recurring operating costs incurred to operate the business. The Company respectfully submits that, under the

Staff’s own framework in Question 100.01 of the C&DI—which evaluates the nature, effect, and context of an adjustment—the exclusion of the purchase of royalty interest from Adjusted EBITDA and Adjusted Net Income does not obscure the Company’s operating performance and therefore does not render the measure misleading.

Moreover, the Company has clearly described the nature of the purchase of the royalty interest and the rationale for the adjustment, reconciled Adjusted EBITDA and Adjusted Net Income to the most directly comparable GAAP measures, and presented the GAAP measures with equal or greater prominence. The adjustment is applied consistently and is not selectively applied to exclude only unfavorable items.

stated in our Non-GAAP Measures disclosure in our periodic reports, Adjusted EBITDA is intended to facilitate period-over-period comparability by excluding items that “occur with inconsistent frequency,” “obscure underlying business trends,” or relate to “discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.” We believe the adjustment provides investors with a clear and meaningful view of our underlying business trends, aligns with how management evaluates the business and enhances comparability across periods.

For these reasons, as well as the reasons set forth in the Company’s prior responses to the Staff’s comments, the Company believes that excluding the purchase of the royalty interest from Adjusted EBITDA and Adjusted Net Income provides investors with a more meaningful depiction of the Company’s underlying operating performance and is consistent with

Regulation G and the guidance in Question 100.01 of the C&DI.

In future filings, the Company will supplement its disclosure regarding the adjustment to provide additional detail and context for why the Company believes such adjustment is useful to investors as follows:

“Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.”

2. We have reviewed your response to comment 3 and we believe that the non-GAAP adjustment for

Inventory step-up in connection with acquired businesses is inconsistent with Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures. Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.

Response:

We respectfully acknowledge the Staff’s comment. The Company continues to believe that its non-GAAP adjustment for Inventory step-up in connection with acquired businesses

(i) is appropriate and consistent with Question 100.04 of the C&DI and the requirements of Rule 100(b) of Regulation G, (ii) enhances comparability between periods by removing the one-time, transaction-related Inventory step-up expense arising from the application of purchase accounting under GAAP that is not a reflection of our current or ongoing cost to manufacture product, and (iii) provides investors with a better understanding of the Company’s business performance and underlying gross margin trends. The adjustment is intended to eliminate the impact of a one-time, transaction-related step-up to reflect cost of goods sold as if such acquired inventory had been produced by the Company and sold in the ordinary course of business, absent which we believe the Company’s gross margins would have been viewed by investors as artificially low and distorted during the period when step-up charges were recognized in cost of goods sold. We believe that such an adjustment is particularly useful to investors in the context of a significant acquisition of a company that is engaged in the inventory and capital-intensive large joint implant business, such as Lima, which had approximately 16 months of inventory on hand as of the date of acquisition. We believe that this adjustment significantly enhanced comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance. This is further evidenced by the fact that following the completion of amortization of the Inventory step-up from its recently acquired businesses, the Company’s

GAAP gross margin remains on trend with our previously reported adjusted gross margins.

However, we understand and respect the Staff’s position and will remove this non-GAAP adjustment from our presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in press releases on Form 8-K.

Read in the reply
In its next report

First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.

Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.

New paragraph

(7) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, the following non-GAAP measures for the three months ended April 4, 2025 as presented in our Form 10-Q for the period ended April 4, 2025 have been revised to reflect the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses: Adjusted EBITDA for our Recon segment has been revised from $68.3 million to $56.2 million, Total Adjusted EBITDA has been revised from $99.2 million to $87.1 million, Adjusted EBITDA margin for our Recon segment has been revised from 23.9% to 19.6%, and Total Adjusted EBITDA margin has been revised from 17.7% to 15.6%.

0 words cut, 139 added sec.gov
New paragraph

(1) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the three months ended April 4, 2025 has been revised from $99.2 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $87.1 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted EBITDA margin for the three months ended April 4, 2025 from 17.7%, as presented in our Form 10-Q for the period ended April 4, 2025, to 15.6%.

0 words cut, 123 added sec.gov
New paragraph

(1) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for our Recon segment for the three months ended April 4, 2025 has been revised from $68.3 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $56.2 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted EBITDA margin for our Recon segment for the three months ended April 4, 2025 from 23.9%, as presented in our Form 10-Q for the period ended April 4, 2025, to 19.6%.

0 words cut, 131 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Measures, page 31
SEC asked (3)
We note your response to prior comment 4. To the extent that the non-GAAP adjustments for strategic transaction costs continue to be material to the non-GAAP measures, in future filings please include more detailed quantitative and qualitative information about the nature of the adjustments, similar to your response.
ENOV answered
We respectfully acknowledge the Staff’s comment. We have included more detailed quantitative and qualitative information about the nature of such adjustments in our Form 10-K for the year ended December 31, 2025, and will continue to provide such information in future filings to the extent that non-GAAP adjustments for strategic transaction costs continue to be material to our non-GAAP measures.

10-K for the Fiscal Year Ended December 31, 2025

Consolidated

Financial Statements

Note

19. Segment Information, page 106
Read in the reply
In its next report

First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.

Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.

Reworded

Adjusted EBITDA excludes from Net income (loss) the effect of Loss Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other (income) expense, net; non-operating (gain) loss on investments; debt extinguishment charges; Interest expense, net; Restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and goodwill impairment charges; and fair value charges on acquired inventory. charges. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted Adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

70 words cut, 8 added sec.gov
Reworded

(5) Strategic transaction costs includes: (i) $9.2 $7.4 million for the three months ended October April 3, 2025 2026 and $17.5 $8.7 million for the three months ended September 27, 2024 April 4, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to be the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company (in each case, such costs relate solely to roles eliminated or that in connection with the integration of the Lima acquisition, and are dedicated to integration activities, non-recurring and not part of our normal business operations); (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 $3.4 million for the three months ended October April 3, 2025 2026 and $2.6 $2.9 million for the three months ended September 27, 2024 April 4, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $0.4 $0.2 million for the three months ended October April 3, 2025 2026 and $1.3 $0.5 million for the three months ended September 27, 2024, April 4, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

29 words cut, 107 added sec.gov
Reworded

Selling, general and administrative expense increased $13.7 $13.8 million in the three months ended October April 3, 2025 2026 compared to the prior year period, primarily due to a $9.2 $4.6 million increase in commissions on increased sales and sales, increased investment in the business in selling, general and administrative costs of $10.3 $7.7 million, offset by and a $5.7 $1.1 million decrease increase in strategic transactions transaction costs driven by a reduction in acquisition integration costs.

15 words cut, 10 added sec.gov

Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.

Consolidated Financial Statements · Note 19. Segment Information, page 106
SEC asked (4)
We note your response to comment 1 and reissue in part. Please disclose how the CODM uses the reported measure of segment profit or loss in assessing segment performance and deciding how to allocate resources in future filings. Refer to ASC 280-10-50-29(f) and the example in ASC 280-10-55-47(bb).
ENOV answered
We respectfully acknowledge the Staff’s comment. We have revised our disclosure in our Form 10-K for the year ended December 31, 2025 in response to the Staff’s comment, and will continue to provide such disclosure in future filings.
Read in the reply
In its next report

First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.

The part of the filing the question names could not be found in both reports. Read them on sec.gov.

Also in this review: closing letter, 2026-04-23

Form 10-Q for the Fiscal Quarter Ended April 4, 2025

2025-07-22 to 2025-08-05 · 1 question · 1 letter from the SEC, 1 from the company
No closing letter
Non-GAAP measuresLiquidity and cash
Operations · Non-GAAP Measures, page 26
SEC asked
We have the following comments regarding your response to comment 5 related to the adjustment for the purchase of royalty interest. In your response, you state that the product development agreements have been "terminated" while the disclosure on page 16 of the Form 10-Q indicates that the buyout of the economic interest in future royalty payments was for "existing" product development agreements related to certain
Rest of the question

of the Company’s U.S. reconstructive products. Please clarify in your response if the product development agreements continue to be in effect and if the underlying intellectual property continues to be incorporated in your reconstructive products subsequent • 1. to the buyout. • Tell us how many product development agreements were bought out and if you continue to have any royalty driven agreements with product development partners. Explain the methodology that was used to determine the buyout amount. • Elaborate on your shift to a new model for product development projects and how buying out the royalty generating model accelerated that shift. • We reference the disclosure on page 16 of the Form 10-Q that the gross payout under the buyout agreements is $ 43.8 million, which will be paid over seven years. We also note in your response that the payments may be structured over time to manage cash flow impacts. Explain how you determine the amount to be paid each year under the buyout agreement and if it is dependent on future operational factors.

ENOV answered
, you state that the product development agreements have been “terminated” while the disclosure on page 16 of the Form 10-Q indicates that the buyout of the economic interest in future royalty payments was for “existing” product development agreements related to certain of the

Company’s U.S. reconstructive products.
Rest of the answer

Please clarify in your response if the product development agreements continue to be in effect and if the underlying intellectual property continues to be incorporated in your reconstructive products subsequent to the buyout.

Tell us how many product development agreements were bought out and if you continue to have any royalty driven agreements with product development partners. Explain the methodology that was used to determine the buyout amount.

Elaborate on your shift to a new model for product development projects and how buying out the royalty generating model accelerated that shift.

We reference the disclosure on page 16 of the Form 10-Q that the gross payout under the buyout agreements is $ 43.8 million, which will be paid over seven years. We also note in your response that the payments may be structured over time to manage cash flow impacts. Explain how you determine the amount to be paid each year under the buyout agreement and if it is dependent on future operational factors.

Response:

We respectfully acknowledge the Staff’s comment and advise the Staff as follows with respect to the points set forth in the comment above:

The relevant product development agreements were terminated in connection with the buyout transactions and are no longer in effect. The Company will revise its disclosure in future filings to clarify this point. The underlying intellectual property developed in connection with such agreements continues to be incorporated in the Company’s products subsequent to the buyout transactions.

In connection with the transition to the Company’s new model for product development activities, the Company has bought out fourteen legacy product development agreements with its leading product development partners who will now provide product design and development and consulting services across an expanded sector of the Company’s portfolio (i.e., hip and knee, shoulder, enabling technologies). For the year ended December 31, 2024, these agreements accounted for approximately 60% of the total product royalties paid by the Company’s reconstructive segment. Excluding the impact of the buyout agreements, the Company anticipates that its total product development-related expenses and continuing royalty expenses for 2025 and future periods will be comparable to or greater than the amount of its royalty expenses for 2024.

The buyout amounts with respect to such agreements were determined by arms-length negotiations with the counterparties and represent the parties’ reasonable, good faith estimate of the fair market value of the economic interest of the intellectual property rights under the terminated product development agreements. The timing of the payments to the counterparties was determined by individual negotiations, and a discount rate commensurate with the agreed-upon timing of the settlement payments was applied. The Company continues to have individual project-based, royalty-driven agreements with other development partners. However, the Company believes that the number and prevalence of these agreements will continue to decrease over time as (i) a greater proportion of product development activity is handled by partners whose agreements are structured under the new model and (ii) other remaining legacy product development agreements are terminated or expire.

As noted in our prior response, the Company has moved to a new model for product development projects. The model reflects a strategic shift and is intended to incentivize contributions of intellectual property across an expanded sector of the Company’s entire portfolio of surgical implants, instrumentation and emerging technologies rather than individual projects. The Company believes that this new model, which primarily aligns compensation with growth in the Company’s overall Reconstructive portfolio rather than individual products, will accelerate its pace of innovation by, among other things

(i) incorporating new and diverse viewpoints to ensure that global and regional differences and preferences are considered in the product development process, (ii) ensuring that the Company receives candid and unbiased guidance in integrating and rationalizing acquired product portfolios, (iii) placing additional emphasis on rapidly developing and expanding enabling technologies, and (iv) fostering an environment that encourages product development partners to provide strategic advice on research and development activities that cut across individual product and product lines.

As noted above, a key benefit of the new model is the emphasis it places on candid and unbiased advice in the product development process. Under the Company’s legacy project-focused approach to innovation, product development partners were incentivized to devote their time and attention to projects to which they are assigned and to products for which they receive royalties. Consequently, these prominent partners with considerable clinical and design expertise are not incentivized to provide broader ideas or innovative insights beyond the scope of their discrete engagements and thus are less likely to provide high value innovative ideas to the Company in the project-focused consulting setting because there are no incentives to do so. Specifically, under the legacy model, if an idea for a next generation product could disrupt the existing portfolio or sunset certain products for which a product development partner currently receives royalties, they may be disincentivized from pursuing such an idea. By buying out the legacy agreements with its leading product development partners, the Company was able to significantly accelerate the shift to the new model by eliminating these disincentives, while also ensuring that it fulfilled its pre-existing contractual obligations under the legacy agreements through the negotiated settlements.

The amounts to be paid each year under the buyout agreements are fixed and are not dependent on future operational factors. As noted in the second bullet above, such buyout amounts were determined on an individual basis as a result of arms-length negotiations with the counterparties and represent the parties’ reasonable, good faith estimate of the fair market value of the economic interest of the intellectual property rights under the terminated product development agreements.

Read in the reply
In its next report

First report after the company's reply of Aug 5, 2025: 10-Q filed Aug 7, 2025 ↗, against the 10-Q filed May 8, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-K for the Fiscal Year Ended December 31, 2024

2025-06-27 to 2025-07-14 · 4 questions · 1 letter from the SEC, 1 from the company
No closing letter
Non-GAAP measuresAcquisitionsSegmentsResults discussion (MD&A)
Operations · Non-GAAP Measures, Adjusted EBITDA; Comparable Sales, page 41
SEC asked (1)
Please revise future filings to reconcile Adjusted EBITDA to the most comparable GAAP measure, net loss. In addition, we note that you present Adjusted EBITDA margin without presenting the most directly comparative GAAP measure. Please revise future filings to present the GAAP measure, which appears to be net income (loss) margin, with equal or greater prominence.
Rest of the question

Refer to Item 10(e)(1)(i)(A) and (B) of Regulation S-K and Questions 102.10(a) and Question 103.02 of the Compliance & Disclosure Interpretations for Non-GAAP Financial Measures. Please also apply to your non-GAAP presentations presented in exhibits to Form 8-K.

ENOV answered
We respectfully acknowledge the Staff’s comment and advise the Staff that in future filings, we will reconcile Adjusted EBITDA to net income (loss) and will present GAAP measures with equal or greater prominence to any comparable non-GAAP measures also presented, including with respect to presentations of net loss, Adjusted EBITDA, net income (loss) margin and Adjusted EBITDA margin. The Company will also apply the foregoing to any non-GAAP presentations presented in exhibits to future Form 8-K filings.
Read in the reply
In its next report

First report after the company's reply of Jul 14, 2025: 10-Q filed Aug 7, 2025 ↗, against the 10-Q filed May 8, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Operations · Non-GAAP Measures, Adjusted EBITDA; Comparable Sales, page 41
SEC asked (2)
We see that adjusted EBITDA includes a non-GAAP adjustment for "Strategic transaction costs" of $78.3 million, which appears to include costs related to the acquisition and integration of Lima in 2024 as well as other business development initiatives and integration costs of recent acquisitions.
Rest of the question

With a view towards understanding how the non-GAAP adjustment complies with Question 100.01 of the Compliance & Disclosure Interpretations for Non-GAAP Financial Measures, please describe in detail, the nature and composition of the strategic transaction costs, including the nature of the acquisition and integration charges and other business development initiatives. Provide us with a quantitative breakdown of each category of costs for each period presented. As part of your response, explain your consideration of whether these strategic transaction costs represent normal, recurring, cash operating expenses necessary to operate your business.

ENOV answered
We respectfully acknowledge the Staff’s comment. Strategic transaction costs include costs incurred in the first 24-36 months post-acquisition to integrate recently acquired businesses (e.g., specific costs and expenses related to rebranding, payroll and retention, restructuring or termination of sales relationships, distributor network rationalization, integration and migration of IT systems, ERP rationalization, deal costs, legal entity rationalization and other integration-related activities) and specific costs related to the consummation of the acquisition process.
Rest of the answer

For the years ended December 31, 2024, 2023 and 2022, the charges consisted of the following expenses/(benefits) (amounts in millions):

2024

2023

2022

Lima related acquisition and integration costs:

Payroll costs and retention expenses(1)

$

13.1

—

Integration and migration of IT systems

12.5

Deal costs(2)

15.4

8.3

Rebranding costs(3)

5.9

Operational integration costs(4)

17.9

0.7

Other strategic transaction costs:

Other (non-Lima) acquisition integration costs(5)

6.9

8.4

5.8

Separation related costs(6)

4.6

20.6

54.9

Other charges(7)

1.9

0.3

Total Strategic transaction costs

78.3

38.3

61.0

(1)

Includes payroll and retention costs for roles to be eliminated or that are dedicated to integration activities.

(2)

Includes professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation.

(3)

Includes integration related costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling.

(4)

Includes non-recurring integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation.

(5)

Includes integration related payroll and severance costs, ERP integration and migration costs, and costs associated with sales agent and distributor network rationalization. For 2024, such costs primarily relate to Novastep ERP transition ($5.6 million). For 2023, such costs primarily relate to Novastep ($5.0 million) and Mathys ($3.4 million) integration activities. For 2022, such costs represent Mathys integration activities, comprised primarily of product rationalization related expenses ($4.0 million).

(6)

Represents non-recurring costs, including professional fees, retention expenses, rebranding and marketing costs, and other costs associated with the Separation of our former fabrication technology business through a tax-free, pro-rata distribution of the common stock of ESAB Corporation to our shareholders.

(7)

Represents other non-recurring charges, including global ERP rationalization project costs and shared service center start-up costs.

respectfully advise the Staff that our policy for including such strategic transaction costs as non-GAAP adjustments requires, among other things, that only costs that are necessary to consummate the acquisition and integrate the acquired business are eligible for such treatment. Such costs are not normal, recurring, cash operating expenses necessary to operate our business, as they do not reflect our normal operating activity, represent short term additional payments or expenses which will not continue in the future, and are solely related to the objective of successfully integrating the acquired business.

Read in the reply
In its next report

First report after the company's reply of Jul 14, 2025: 10-Q filed Aug 7, 2025 ↗, against the 10-Q filed May 8, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Operations · Non-GAAP Measures, Adjusted EBITDA; Comparable Sales, page 41
SEC asked (3)
As a related matter, in future filings, please revise your reconciliation of adjusted EBITDA to include footnote disclosure discussing the nature of each non-GAAP adjustment that includes multiple items, such as "MDR and other costs" and "strategic transaction costs".
Rest of the question

Please include disclosure about why you believe these adjustments are not normal, recurring, cash operating expenses necessary to operate your business. Please also apply to your non-GAAP presentations presented in exhibits to Form 8-K.

ENOV answered
We respectfully acknowledge the

Staff’s comment and advise that Staff that in future filings, we will revise our reconciliation of adjusted EBITDA to include footnote disclosure discussing the nature of each non-GAAP adjustment that includes multiple items. We will also include disclosure about why we believe these adjustments are not normal, recurring, cash operating expenses necessary to operate our business. The Company will also apply the foregoing to any non-GAAP presentations presented in exhibits to future Form 8-K filings.
Read in the reply
In its next report

First report after the company's reply of Jul 14, 2025: 10-Q filed Aug 7, 2025 ↗, against the 10-Q filed May 8, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Operations · Non-GAAP Measures, Adjusted EBITDA; Comparable Sales, page 41
SEC asked (4)
We reference the presentation for non-GAAP comparable sales by segment and in total along with the disclosure on page 41 that "Comparable Sales and Comparable Sales Growth rate are presented for illustrative purposes only and do not and are not intended to comply with Article 11 of Regulation S-X promulgated by the SEC in respect of proforma financial information, and may differ, including materially, from proforma
Rest of the question

financial statements presented in accordance therewith." Please note that disclosure of combined amounts that are not calculated under the guidance in Article 11 of Regulation S-X would not be appropriate as a Non-GAAP measure. See guidance in Question 100.05 of the Compliance & Disclosure Interpretations for Non- GAAP Financial Measures. To the extent you intend to include combined information in future filings, please ensure the combined information is prepared and presented in compliance with the pro forma financial statement requirements of Article 11 of Regulation S-X. Please also apply to your non-GAAP presentations presented in exhibits to Form 8-K. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Non-GAAP Measures, page 26 We note your non-GAAP measures for the three months ended March 31, 2025 include a $36 million adjustment for the purchase of royalty interest, which represents a strategic purchase of economic interest on future royalty payments in your intellectual property over the next seven years. Please explain to us the nature of the underlying intellectual property, the structure of future payments under the existing product development agreements and why you decided to purchase the economic interest on future royalty payments. Please tell us how you considered whether these 5. costs are a normal, recurring operating expense for which a non-GAAP adjustment would be inconsistent with Question 100.01 of the Compliance & Disclosure Interpretations for Non-GAAP Financial Measures.

ENOV answered
We respectfully acknowledge the Staff’s comment and advise the

Staff that in future filings, we will revise any disclosure involving combined information, including with respect to “Comparable Sales” and “Comparable Sales Growth Rate” to the extent we present these measures in future filings for the acquisition or disposition of a business, to ensure that such combined information is prepared and presented in compliance with the pro forma financial statement requirements of Article 11 of Regulation

S-X.
Read in the reply
In its next report

First report after the company's reply of Jul 14, 2025: 10-Q filed Aug 7, 2025 ↗, against the 10-Q filed May 8, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Form 10-K for the Fiscal Year Ended December 31, 2021

2022-11-22 to 2022-12-08 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2022-12-08
Non-GAAP measuresSegmentsResults discussion (MD&A)Income taxes
Condensed Consolidated Financial Statements for the Nine Months Ended September 30, 2022 · Note 14. Segment Information, page 23
SEC asked
We note that you reconcile segment Adjusted EBITDA to operating loss. Please explain to us how this reconciliation is consistent with the guidance in ASC 280-10-50-30(b) that requires a reconciliation of the reportable segments' measures of profit or loss to consolidated income before income taxes and discontinued operations.
Rest of the question

In addition, tell us how you considered Question 103.02 of the Compliance & Disclosure Interpretations for Non-GAAP Financial Measures dated April 4, 2018 in your reconciliation to Adjusted EBITDA (non-GAAP) in MD&A on pages 31 and 32.

ENOV answered
We acknowledge and appreciate the Staff’s comments. Regarding our segment footnote presentation and reconciliation pursuant to ASC 280-10-50-30(b), in future filings we will revise the tabular reconciliation included in the “Segment Information” footnote to our financial statements to reconcile the total of our reportable segments’ measure of profit and loss (segment Adjusted EBITDA) to consolidated Income (loss) from continuing operations before income taxes.

In response to the Staff’s comment regarding our reconciliation to Adjusted EBITDA (non-GAAP) in the MD&A on pages 31 and 32 of our
Rest of the answer

Form 10-Q for the quarterly period ended September 30, 2022, in future filings we will revise our presentations by no longer including a table reconciling consolidated Operating loss (GAAP) to Adjusted EBITDA (non-GAAP), and related margin percentages, such as the table that appeared on page 31 of the Form 10-Q for the quarterly period ended September 30, 2022. In addition, in future filings we will revise the tables which currently reconcile operating income (loss) to Adjusted EBITDA by segment and at the consolidated level, such as the tables that appeared on page 32 of the Form 10-Q for the quarterly period ended September 30, 2022, to instead reconcile from Net income (loss) from continuing operations to Adjusted EBITDA at the consolidated level and for each of our reportable segments. In the context of these tables, we will also present corresponding GAAP and non-GAAP margins.

Read in the reply
In its next report

First report after the company's reply of Dec 6, 2022: 10-K filed Mar 1, 2023 ↗, against the 10-K filed Feb 22, 2022 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2022-12-08

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-10-04 to 2018-10-23 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-10-23
Risk factorsRussia and UkraineRevenue
Risk Factors, page 7 · We have done and may continue to do business in countries subject to U.S. sanctions…, page 10
SEC asked (1)
In your letter to us dated May 26, 2015, you discussed contacts with Sudan and Syria. Your disclosure does not discuss contacts with those countries. As you know, Sudan and Syria are designated by the State Department as state sponsors of terrorism and are subject to U.S. sanctions and/or export controls.
Rest of the question

Please describe to us the nature and extent of any past, current, and anticipated contacts with Sudan and Syria since the 2015 letter, including with their governments, whether through subsidiaries, distributors, resellers, affiliates, or other direct or indirect arrangements. Please also discuss the materiality of any contacts, in quantitative terms and in terms of qualitative factors that a reasonable investor would deem important in making an investment decision. Tell us the approximate dollar amounts of any revenues, assets and liabilities associated with Sudan and Syria for the last three fiscal years and the subsequent interim period. Finally, tell us whether any contacts involve dual use products and, if so, the nature of the dual uses.

ENOV answered
There were no sales to Syria since the 2015 letter. The Company identified a single transaction valued at 41,536 INR (approximately $641.70) for welding training services provided in India by our Indian ESAB subsidiary to a company based in Sudan. The services were provided to the Sudan-based company in November 2017 after the Office of Foreign Assets Control (OFAC) effectively lifted its embargo on Sudan.[1]

Provision of the services was not prohibited under U.S. sanctions or export control regulations and did not involve export controlled dual use products.
Rest of the answer

The transaction was not quantitatively or qualitatively material.

We do not anticipate future material contacts with Sudan or Syria.

Read in the reply
In its next report

First report after the company's reply of Oct 15, 2018: 10-Q filed Oct 25, 2018 ↗, against the 10-Q filed Aug 6, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Risk Factors, page 7 · We have done and may continue to do business in countries subject to U.S. sanctions…, page 10
SEC asked (2)
Section 3.23 of the September 24, 2017 Purchase Agreement between you and Circor International, Inc. sets forth a representation that, except as described in Section 3.23 of your Disclosure Letter, the fluid handling business is being, and since September 1, 2012 has been, conducted in compliance with all applicable United States import, export control and sanctions laws and regulations.
Rest of the question

Please tell us whether those exceptions relate to Sudan, Syria or North Korea.

ENOV answered
The exceptions noted in Section 3.23 of the September 24, 2017 Purchase Agreement between us and Circor do not relate to Sudan, Syria, or North Korea.

The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the filing.
Read in the reply
In its next report

First report after the company's reply of Oct 15, 2018: 10-Q filed Oct 25, 2018 ↗, against the 10-Q filed Aug 6, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-10-23

Form 10-K

2016-04-26 to 2016-05-26 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2016-05-26
Executive pay
Item 11. Executive Compensation, page 94
SEC asked
Please revise future filings to clarify how the compensation you pay relates to your executive compensation philosophy and practices. For example, your disclosure refers to the linkage of equity awards and stock price, which you disclose incentivizes long-term success. You also disclose that the long-term incentive plan aligns the rewards of executives with the interests of stockholders.
Rest of the question

However, considering the stock price decline you note and other equity awarded to your named executive officers in 2015 and earlier, it is unclear why the 2015 Special Grants were needed to motivate and retain and how such awards were “sufficiently aligned” with stockholder interests. That is, how did your compensation committee conclude that the interests of your named executives’ were aligned with shareholders as a result of the Special Grants? Given the stock price decline noted in your disclosure, it is unclear how those awards furthered an alignment of those interests. Additionally, your disclosure appears to attribute the stock price decline and inability to meet the performance criteria for previously awarded PRSUs to external factors, such as commodity price declines. Please clarify how you considered these factors in determining the performance of your named executives. Please also clarify how the previously awarded PRSUs “tie directly to performance” given the new PRSUs awarded as part of the Special Grants. Finally, you disclose that you do not permit the repricing of underwater options; however, the Special Grants appear to have a similar function and purpose, but without the shareholder approval you indicate would be necessary to re-price.

ENOV answered
In future filings, we will enhance our disclosures to further clarify how the different elements of our executive compensation program relate to and implement our compensation philosophy. We address below some of the disclosures in the Compensation Discussion and Analysis (“CD&A”) included in our Definitive Proxy Statement as filed with the

Commission on April 1, 2016 (the “DEF14A”) which we believe address the points raised in the Comment Letter.

The elements of our executive compensation program are intended to implement the objectives of our compensation philosophy, as described in the
Rest of the answer

DEF14A at page 20, and to work together, incentivizing performance over different time horizons and encouraging executives to drive long-term Company success that, we believe, will ultimately deliver sustainable, long-term stockholder returns. The goal or purpose of our Annual Incentive Plan is “[t]o reward our executive officers for achievement in key areas of the Company and, if applicable, business operational and financial performance, as well as to recognize the executive’s individual performance during the year.” DEF14A at page 21. The purpose of our long-term incentives, consisting of stock options and performance-based restricted stock units (“PRSUs”), is to “align the rewards of executives with the interests of stockholders by encouraging sustained and superior long-term operational and financial performance and increases in stockholder returns over an extended period of time.” DEF14A at page 21. Thus, annual incentive payouts are tied to current year performance, whereas long-term incentives are designed to advance our Company objectives over a multi-year period.

1[B].

You also disclose that the long-term incentive plan aligns the rewards of executives with the interests of stockholders. However, considering the stock price decline you note and other equity awarded to your named executive officers in 2015 and earlier, it is unclear why the 2015 Special Grants were needed to motivate and retain and how such awards were “sufficiently aligned” with stockholder interests. That is, how did your compensation committee conclude that the interests of your named executives’ were aligned with shareholders as a result of the Special Grants? Given the stock price decline noted in your disclosure, it is unclear how those awards furthered an alignment of those interests.

Response:

In deciding to award the 2015 Special Grants, the Compensation Committee of our Board of Directors (the “Compensation

Committee”) evaluated whether previously granted options and PRSUs were continuing to fulfill their motivational and retention objectives, and were sufficiently aligned with our Company goals and stockholder interests. In assessing this, the Compensation Committee considered a number of factors, including commodity prices, currency pressures, general economic conditions and the dynamics of our end-markets, and stock market declines during late 2014 and 2015. See DEF14A page 19. For more information on the specific external factors considered by our Compensation Committee, see pages 27 and 26 of the 10-K noting the role that a sustained decline in commodity prices, including oil, and fluctuations in currency exchange rates have played in our recent operations and results. The Compensation Committee believed that, partially because of such external factors, the exercise prices of previously granted stock options and the possibility that previously granted PRSUs may not be earned made these prior equity grants unlikely to be motivational or to serve their retention objectives, despite the fact that we have achieved transformative growth and accomplished many strategic achievements since 2012. Following this evaluation, the Compensation Committee determined to make the 2015 Special Grants. The 2015 Special Grants are designed to align with our stockholders’ interests in the same manner as past equity awards: by helping to retain and motivate our executives by offering a potential reward that is based on improved future financial performance and increases in share values.

1[C].

Additionally, your disclosure appears to attribute the stock price decline and inability to meet the performance criteria for previously awarded PRSUs to external factors, such as commodity price declines. Please clarify how you considered these factors in determining the performance of your named executives. Please also clarify how the previously awarded PRSUs “tie directly to performance” given the new PRSUs awarded as part of the Special Grants.

As noted throughout our CD&A, fiscal 2015 results did not meet our expectations, notwithstanding the positive factors regarding our 2015 accomplishments noted on page 18. The table on page 18 shows precisely how under-performance on our pre-established corporate performance metrics resulted in achieving a payout at only 52% of target under our Annual

Incentive Plan. In addition, as explained on page 19 of our CD&A, even though our stock price outperformed our peers’ from 2010 until near the end of 2015, our executives shared the impact of our stock price decline through “diminished realizable pay” from the options and unearned PRSUs that had been granted over the prior four years. These awards and the 2015 Special Grants are tied to performance by having value, if at all, that is based on our stock price performance and, in the case of PRSUs, through terms for earning the PRSUs that are based on earnings per share growth goals.

1[D].

Finally, you disclose that you do not permit the re-pricing of underwater options; however, the Special Grants appear to have a similar function and purpose, but without the shareholder approval you indicate would be necessary to re-price.

We respectfully note that the 2015 Special Grants were distinct awards tied to future performance and did not constitute repricings. Section 3.3 of the Company’s 2008 Omnibus Incentive Plan, as amended and restated (the “Plan”), provides as follows in pertinent part:

“…the Company may not, without obtaining stockholder approval: (a) amend the terms of outstanding Options or SARs to reduce the

Option Price or SAR Exercise Price of such outstanding Options or SARs; (b) cancel outstanding Options or SARs in exchange for or substitution of Options or SARs with an Option Price or SAR Exercise Price that is less than the Option Price or

SAR Exercise Price of the original Options or SARs; or (c) cancel outstanding Options or SARs with an Option Price or SAR Exercise Price above the current stock price in exchange for cash or other securities.”

This Plan language applies to the amendment or cancellation of outstanding option or SAR awards. The Company has neither amended nor cancelled any outstanding awards and will not do so without the requisite stockholder approval. The 2015 Special Grants were new grants of options and PRSUs that are subject to vesting over different periods than the outstanding awards and, for the PRSUs, have different performance metrics, and were not granted in exchange for or substitution of any of the outstanding equity awards. Furthermore, please note that the above Plan provision does not apply to any award types other than options and SARs, and therefore is inapplicable with respect to the PRSUs.

Closing

The Company acknowledges that:

•

The Company is responsible for the adequacy and accuracy of the disclosure in the filing;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of May 9, 2016: 10-Q filed Jul 28, 2016 ↗.

No earlier 10-Q before the SEC's letter is in Tickdelta, so there is nothing to compare with.

SEC asked
We note your response to prior comment 1. If you believe your stock price relates to the alignment of the interests of shareholders with the rewards to your executives, as indicated in your response, it continues to be unclear how you determined such interests are aligned as a result of the Special Grants.
Rest of the question

Specifically, how did you consider the stock price decline noted in your disclosure in determining the alignment of those interests and to award the Special Grants? We note that according to your disclosure, the Special Grants permit your executives an additional opportunity to be rewarded, with performance measured and exercise prices set at the grant date, following the decline in your stock price. However, it does not appear that your shareholders will have a similar opportunity to benefit, as those who continue to hold shares will do so at a lower price. Please revise to clarify. Additionally, while we note you have not “amended or cancelled” or repriced any outstanding awards, the options awarded as part of the Special Grants appear to achieve a similar purpose. That is, as your disclosure notes, those grants were made at least in part due to prior grants being underwater.

ENOV answered
In future filings, Colfax will revise the discussion of factors considered by the Compensation Committee in approving special grants, such as the 2015 Special Grants and the 2016 CEO Grant, to more clearly identify how the factors considered by the Compensation Committee contributed to its determinations.
Rest of the answer

For example, with respect to the 2015 Special Grants, after considering the factors discussed in the CD&A and the Prior Response, including the factors that the Compensation Committee viewed as contributing to the Company’s recent stock price performance, the Compensation Committee determined that the decline in the value of previously earned equity held by the executive officers continued to align those executives’ interests with the long-term interests of shareholders but that the performance-based restricted stock units and stock options granted in

2014 and 2015 were no longer operating to advance shareholder interests by retaining and motivating Colfax executives. The Compensation Committee determined that the design of Colfax’s long-term incentives remained appropriate, but that different stock price and performance targets were needed, in the Compensation Committee’s view, to advance shareholders’ interests by establishing new objectives for certain of Colfax’s executives. Based on these determinations, the

Compensation Committee approved the 2015 Special Grants.

The 2015 Special Grants differ from equity repricings in several respects. Under

Instruction 2 to Item 402(c)(2)(v) and (vi) of Regulation S-K, only the incremental value (if any) of a repriced equity award is reported in the Summary Compensation Table. In contrast, the full value of the 2015 Special Grants was reported in Colfax’s 2015 Summary Compensation Table. In addition, because the 2015 Special Grants were not granted in exchange for or upon cancellation of earlier equity awards, those earlier equity awards continue to count against the number of shares that are available for issuance under Colfax’s Omnibus Incentive Plan and continue to be included in calculations of “overhang” and potential dilution from Colfax’s equity compensation program. Accordingly, Colfax respectfully believes that the 2015 Special Grants are not equivalent to repricings of those earlier equity awards.

Closing

The Company acknowledges that:

•

The Company is responsible for the adequacy and accuracy of the disclosure in the filing;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: closing letter, 2016-05-26

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 20 letters filed since 2016-04-26. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.